Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference
EDINBURGH, United Kingdom , Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz , Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on December 3 rd and 4 th , 2019.
View HTML
Toggle Summary NuCana to Present at the Jefferies 2019 London Healthcare Conference
EDINBURGH, United Kingdom , Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 London Healthcare Conference in London, UK .
View HTML
Toggle Summary NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update
Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer Cash and Cash Equivalents to Fund Operations into the Second Half of 2021 Numerous Clinical
View HTML
Toggle Summary NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON , Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced results from two of its clinical stage ProTides, NUC-3373
View HTML
Toggle Summary NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three Interim Analyses, Including Two Designed to Support Accelerated Approval EDINBURGH, United Kingdom , Oct.
View HTML
Toggle Summary NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
EDINBURGH, United Kingdom , Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in
View HTML
Toggle Summary NuCana to Participate in Citi’s 14th Annual Biotech Conference
EDINBURGH, United Kingdom , Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will host one-on-one meetings at Citi’s 14th Annual Biotech Conference in Boston on September 5 th , 2019.
View HTML
Toggle Summary NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , Aug. 21, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2019 and
View HTML
Toggle Summary Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis
Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to Determine Path Forward Encouraging Survival Trends Observed in Patient Sub-Groups Receiving Acelarin Monotherapy Informs Future Development in Pancreatic Cancer LIVERPOOL, United Kingdom
View HTML
Toggle Summary NuCana Announces First Patients Dosed in Phase I Study of NUC-7738
NUC-7738 is NuCana’s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom , July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment
View HTML